Pharma BD Deal Intelligence
Regeneron Pharmaceuticals, Inc. / ViGeneron GmbH
2022 · Licensing/Option · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2027 at the earliest for this deal, once/if it closes.
Key facts
- Announced Apr 06, 2022
- Deal type Licensing/Option
Related deals
- Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. (2019)
- Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (2026)
- Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) (2022)
- Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. (2025)
- Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. (2026)
- Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (2022)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2022 deals · Regeneron Pharmaceuticals, Inc. deals